<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281396</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDCP-10</org_study_id>
    <nct_id>NCT02281396</nct_id>
  </id_info>
  <brief_title>The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans</brief_title>
  <official_title>A Safety Study of Freeze-dried Rabies Vaccine(MRC-5 Cell)in Chinese Humans From 10-60 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Minhai Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of Freeze-dried Rabies Vaccine （MRC-5
      Cell) in healthy humans aged from 10-60 years old, according to the traditional Essen methods
      (1-1-1-1-1) vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the safety of freeze-dried rabies vaccine (MRC-5 cell) in chinese humans Adverse reactions associated with vaccine</measure>
    <time_frame>within the first 4 weeks after the first vaccination</time_frame>
    <description>Adverse reactions associated with vaccine</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Rabies</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>2.5IU/ml in humans aged 10-20 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5IU/ml in humans aged 21-60 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5IU/ml in humans(from 10-20 years old)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5IU/ml in humans(from 21-60 years old)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old</intervention_name>
    <description>Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval</description>
    <arm_group_label>2.5IU/ml in humans aged 10-20 years old</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old</intervention_name>
    <description>Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval</description>
    <arm_group_label>2.5IU/ml in humans aged 21-60 years old</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)</intervention_name>
    <description>Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval</description>
    <arm_group_label>2.5IU/ml in humans(from 10-20 years old)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)</intervention_name>
    <description>Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval</description>
    <arm_group_label>2.5IU/ml in humans(from 21-60 years old)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10-60 years old healthy people with normal intelligence

          -  Obtain informed consent from the participants or their guardians, and signed informed
             consent

          -  The participants or their guardians can comply with the requirements of clinical trial
             scheme

          -  The axillary temperature is 37.0 ℃ or less

        Exclusion Criteria:

          -  participants who vaccinated with rabies vaccine before

          -  participants who used anti-rabies passive immunization agents

          -  participants who were Suspect or have a history of injury which is hurted by
             warm-blooded mammals

          -  Female who was pregnant, or in the lactation period, or have Pregnant plans in the
             clinical trial.

          -  participants who have allergy history, especially those who are allergic to
             neomycin,or had serious adverse reactions ever, Such as allergies, hives, difficulty
             breathing, angioneurotic edema, or abdominal pain and so on.

          -  participants who had been diagnosed or suspected to have immunodeficiency or
             Autoimmune diseases,or have Immune system disorders.

          -  participants who have Thyroidectomy History,or had been treated because of Thyroid
             disease in the past year.

          -  participants who had abnormal clotting which is diagnosed by doctor(such as clotting
             factor deficiency, coagulation disorders, platelet abnormalities),or who had
             coagulopathy.

          -  Participants who had history of epilepsy, seizures or convulsions ,or family history
             of mental illness.

          -  Participants who is asplenia, or functional asplenia, and asplenia or splenic
             resection under any circumstances.

          -  Participants who had immunosuppressive therapy, cytotoxic therapy, inhaled
             corticosteroids in the past six months. (It does not include Corticosteroid spray
             treatment Of allergic rhinitis, Surface treatment with corticosteroids because of
             acute uncomplicated dermatitis)

          -  Participants who had Received blood products in the past 3 months

          -  Participants who had Received other investigational drug in the past one month.

          -  Participants who had received Live attenuated vaccine 14 days before the clinical
             trial.

          -  Participants who had received Subunit vaccines and inactivated vaccines 7days before
             the clinical trial.

          -  Participants who was having the prevent or the treatment of Antituberculosis.

          -  Participants who had fever 3 days before receiving the Vaccine.( Axillary temperature
             is above 38℃)

          -  Participants who was suffering from severe chronic.( Such as Down's syndrome,
             diabetes, sickle cell anemia or neurological disorder, Guillain-Barre syndrome);

          -  Participants who was diagnosed or suspected to be suffering from some disease, such as
             Respiratory diseases, acute infection, Chronic of active stage，Cardiovascular Disease,
             Severe hypertension, Skin disease ,or the mother or her children was HIV-infected,
             besides the participants were during the Treatment period of malignant tumors,.

          -  According to the researchers, there are other factors that are not suitable for
             Participants to join the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>rabies vaccine</keyword>
  <keyword>MRC-5 cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

